不向美國電信服務分發或在美國傳播
Onco-Innovations Limited (CBOE CA: ONCO)(法蘭克福: W1H, WKN: A3EKSZ)(OTCQB: ONNVF)（&#34; Onco&#34;或&#34; 公司&#34;）宣佈其計劃完成一項非承銷私募（&#34; 私募&#34;），最多發行 2,272,727 個單位（&#34; 單位&#34;），每個單位的價格為 0.88 美元，總募集金額最高可達 2,000,000 美元。每個單位將由一股普通股（每股稱為&#34;股份&#34;）和半個普通股認購權證（每個完整的認購權證稱為&#34;認購權證&#34;）組成，每個認購權證使持有人有權以 1.10 美元的行使價格購買一股股份，有效期為三十六（36）個月。
公司還計劃向一名與公司沒有關聯的第三方發行相當於私募中發行股份總數 1.0% 的股份（&#34;管理費股份&#34;），作為其協助私募的行政費用。
在私募過程中，公司可能會支付介紹費和/或按與認購權證相同的條款發行介紹權證，給予那些幫助引入認購者的合格方。
私募的完成需滿足某些條件，包括但不限於獲得所有必要的監管和其他批准。根據適用的證券法，私募中發行的所有證券將受到四個月零一天的持有期限制。公司計劃將私募的收益用於一般企業和營運資金用途，包括追求公司的運營和研發目標以及投資者關係目的。
此處描述的證券尚未並將不會根據美國 1933 年證券法及其修正案或任何美國州證券法進行註冊，且在未註冊或未獲得相關豁免的情況下不得在美國提供或出售。本新聞稿不構成在美國或任何此類提供、招攬或銷售將是非法的司法管轄區內出售或招攬購買任何證券的要約。
關於 Onco-Innovations Limited
Onco-Innovations 是一家總部位於加拿大的公司，致力於癌症研究和治療，專注於腫瘤學。Onco 的使命是通過開創性的研究和創新解決方案追求癌症的預防和治療。該公司已獲得針對實體腫瘤的專利技術的全球獨家許可。
代表 Onco-Innovations Limited，
&#34; Thomas O'Shaughnessy&#34;
首席執行官
如需更多信息，請聯繫：
Thomas O'Shaughnessy
首席執行官
電話：+ 1 888 261 8055
investors@oncoinnovations.com
CSE 未審查此發佈內容，也不對其準確性或充分性承擔責任。
前瞻性聲明警告。本新聞稿包含前瞻性聲明，包括與私募相關的一般性聲明，以及對資金預期使用和完成日期的預期，以及對公司業務和計劃的一般性聲明，以及其他非歷史事實的聲明。前瞻性聲明通常通過&#34;將&#34;、&#34;可能&#34;、&#34;潛在&#34;、&#34;應該&#34;、&#34;預期&#34;、&#34;期望&#34;及類似表達來識別。除歷史事實聲明外，本發佈中包含的所有聲明均為前瞻性聲明，涉及風險和不確定性。無法保證這些聲明將被證明是準確的，實際結果和未來事件可能與這些聲明中預期的有實質性差異。可能導致實際結果與公司預期有實質性差異的重要因素包括未能按預期完成私募，或根本未能完成，預期收益可能低於預期，未能獲得與私募相關的監管批准，以及公司不時向證券監管機構提交的文件中詳細列出的其他風險。讀者應注意，準備任何前瞻性信息時所使用的假設可能被證明是錯誤的。事件或情況可能導致實際結果與預測有實質性差異，原因是眾多已知和未知的風險、不確定性和其他因素，其中許多超出了公司的控制範圍。讀者應謹慎對待任何前瞻性信息。儘管管理層在準備時認為這些信息是合理的，但可能被證明是錯誤的，實際結果可能與預期有實質性差異。本新聞稿中包含的前瞻性聲明明確受到此警告聲明的限制。本新聞稿中包含的前瞻性聲明是截至本新聞稿日期作出的，公司將根據適用法律的明確要求，公開更新或修訂任何包含的前瞻性聲明。
來源： Onco-Innovations Limited
查看原始新聞稿，請訪問 ACCESS Newswire
<img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTEzMDM4Mg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTEzMDM4Mg"/>

Onco-Innovations Limited 宣佈進行一項非承銷私人配售，最多發行 2,272,727 個單位，每個單位價格為 0.88 美元，目標總收益為 200 萬美元。每個單位包括一股普通股和半個認股權證，認股權證的行使價格為 1.10 美元，有效期為 36 個月。募集的資金將用於一般企業用途和研發。該配售需獲得監管機構的批准，證券將有四個月的鎖定期。該公司專注於癌症研究，並擁有針對實體腫瘤的專利技術的獨佔權

Not for distribution to United States wire services or for dissemination in the United States
<div class="lb-trans">不向美國電信服務分發或在美國傳播
</div>Onco-Innovations Limited (CBOE CA: ONCO)(Frankfurt: W1H, WKN: A3EKSZ)(OTCQB: ONNVF) (&#34; Onco&#34; or the &#34; Company&#34;) announces that it intends to complete a non-brokered private placement (the &#34; Private Placement&#34;) of up to 2,272,727 units of the Company (the &#34; Units&#34;) at a price of $0.88 per Unit, for aggregate gross proceeds of up to $2,000,000. Each Unit shall consist of one common share (each a &#34;Share&#34;) and one-half of one common share purchase warrant (each whole warrant, a &#34;Warrant&#34;), with each Warrant entitling the holder to purchase one Share at an exercise price of $1.10 for a period of thirty-six (36) months.
<div class="lb-trans">Onco-Innovations Limited (CBOE CA: ONCO)(法蘭克福: W1H, WKN: A3EKSZ)(OTCQB: ONNVF)（&#34; Onco&#34;或&#34; 公司&#34;）宣佈其計劃完成一項非承銷私募（&#34; 私募&#34;），最多發行 2,272,727 個單位（&#34; 單位&#34;），每個單位的價格為 0.88 美元，總募集金額最高可達 2,000,000 美元。每個單位將由一股普通股（每股稱為&#34;股份&#34;）和半個普通股認購權證（每個完整的認購權證稱為&#34;認購權證&#34;）組成，每個認購權證使持有人有權以 1.10 美元的行使價格購買一股股份，有效期為三十六（36）個月。
</div>The Company also intends to issue Shares equal to 1.0% of the total of Shares issued in the Private Placement (the &#34;Admin Fee Shares&#34;) to an arm's-length third party, as an administrative fee for their assistance with the Private Placement.
<div class="lb-trans">公司還計劃向一名與公司沒有關聯的第三方發行相當於私募中發行股份總數 1.0% 的股份（&#34;管理費股份&#34;），作為其協助私募的行政費用。
</div>In connection with the Private Placement, the Company may pay finders' fees and/or issue finders' warrants on the same terms as the Warrants, to eligible parties who have assisted by introducing subscribers to the Private Placement.
<div class="lb-trans">在私募過程中，公司可能會支付介紹費和/或按與認購權證相同的條款發行介紹權證，給予那些幫助引入認購者的合格方。
</div>Closing of the Private Placement is subject to certain conditions, including, but not limited to, the receipt of all necessary regulatory and other approvals. All securities issued pursuant to Private Placement will be subject to a hold period of four months and one day pursuant to applicable securities laws. The Company intends to use the proceeds of the Private Placement for general corporate and working capital purposes, including in pursuit of the Company's operational and research and development objectives and for investor relations purposes.
<div class="lb-trans">私募的完成需滿足某些條件，包括但不限於獲得所有必要的監管和其他批准。根據適用的證券法，私募中發行的所有證券將受到四個月零一天的持有期限制。公司計劃將私募的收益用於一般企業和營運資金用途，包括追求公司的運營和研發目標以及投資者關係目的。
</div>The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or any U.S. state securities laws, and may not be offered or sold in the United States absent registration or available exemptions from such registration requirements. This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities in the United States, or in any jurisdiction in which such offer, solicitation or sale would be unlawful.
<div class="lb-trans">此處描述的證券尚未並將不會根據美國 1933 年證券法及其修正案或任何美國州證券法進行註冊，且在未註冊或未獲得相關豁免的情況下不得在美國提供或出售。本新聞稿不構成在美國或任何此類提供、招攬或銷售將是非法的司法管轄區內出售或招攬購買任何證券的要約。
</div>About Onco-Innovations Limited
<div class="lb-trans">關於 Onco-Innovations Limited
</div>Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours.
<div class="lb-trans">Onco-Innovations 是一家總部位於加拿大的公司，致力於癌症研究和治療，專注於腫瘤學。Onco 的使命是通過開創性的研究和創新解決方案追求癌症的預防和治療。該公司已獲得針對實體腫瘤的專利技術的全球獨家許可。
</div>ON BEHALF OF ONCO-INNOVATIONS LIMITED,
<div class="lb-trans">代表 Onco-Innovations Limited，
</div>&#34; Thomas O'Shaughnessy&#34;
<div class="lb-trans">&#34; Thomas O'Shaughnessy&#34;
</div>Chief Executive Officer
<div class="lb-trans">首席執行官
</div>For more information, please contact:
<div class="lb-trans">如需更多信息，請聯繫：
</div>Thomas O'Shaughnessy
<div class="lb-trans">Thomas O'Shaughnessy
</div>Chief Executive Officer
<div class="lb-trans">首席執行官
</div>Tel: + 1 888 261 8055
<div class="lb-trans">電話：+ 1 888 261 8055
</div>investors@oncoinnovations.com
<div class="lb-trans">investors@oncoinnovations.com
</div>The CSE has not reviewed and does not accept responsibility for the accuracy or adequacy of this release.
<div class="lb-trans">CSE 未審查此發佈內容，也不對其準確性或充分性承擔責任。
</div>Forward-Looking Statements Caution. This news release contains forward-looking statements, including in relation to the Private Placement generally, and the anticipated use of funds and closing date thereof, as well as to the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as &#34;will&#34;, &#34;may&#34;, &#34;potential&#34;, &#34;should&#34;, &#34;anticipate&#34;, &#34;expects&#34; and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to complete the Private Placement as contemplated, or at all, that the anticipated proceeds may be lower than expected, the failure to receive regulatory approval in respect of the Private Placement, and other risks detailed from time to time in the filings made by the Company with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward- looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
<div class="lb-trans">前瞻性聲明警告。本新聞稿包含前瞻性聲明，包括與私募相關的一般性聲明，以及對資金預期使用和完成日期的預期，以及對公司業務和計劃的一般性聲明，以及其他非歷史事實的聲明。前瞻性聲明通常通過&#34;將&#34;、&#34;可能&#34;、&#34;潛在&#34;、&#34;應該&#34;、&#34;預期&#34;、&#34;期望&#34;及類似表達來識別。除歷史事實聲明外，本發佈中包含的所有聲明均為前瞻性聲明，涉及風險和不確定性。無法保證這些聲明將被證明是準確的，實際結果和未來事件可能與這些聲明中預期的有實質性差異。可能導致實際結果與公司預期有實質性差異的重要因素包括未能按預期完成私募，或根本未能完成，預期收益可能低於預期，未能獲得與私募相關的監管批准，以及公司不時向證券監管機構提交的文件中詳細列出的其他風險。讀者應注意，準備任何前瞻性信息時所使用的假設可能被證明是錯誤的。事件或情況可能導致實際結果與預測有實質性差異，原因是眾多已知和未知的風險、不確定性和其他因素，其中許多超出了公司的控制範圍。讀者應謹慎對待任何前瞻性信息。儘管管理層在準備時認為這些信息是合理的，但可能被證明是錯誤的，實際結果可能與預期有實質性差異。本新聞稿中包含的前瞻性聲明明確受到此警告聲明的限制。本新聞稿中包含的前瞻性聲明是截至本新聞稿日期作出的，公司將根據適用法律的明確要求，公開更新或修訂任何包含的前瞻性聲明。
</div>SOURCE: Onco-Innovations Limited
<div class="lb-trans">來源： Onco-Innovations Limited
</div>View the original press release on ACCESS Newswire
<div class="lb-trans">查看原始新聞稿，請訪問 ACCESS Newswire
</div><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTEzMDM4Mg" alt="" original-src="https://app.accessnewswire.com/img.ashx?id=1130382"/>

Onco-Innovations 宣佈進行私募 | ONNVF 股票新聞